Journal article 146 views 10 downloads
Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis
,
Mari Jones ,
Rhys Pockett ,
Anya Burton,
Timothy J.S. Cross,
Ian A. Rowe,
Lizz Paley,
Daniela Tataru,
Graeme Alexander,
Aileen Marshall,
Deborah Fitzsimmons
BMJ Open Gastroenterology, Volume: 10, Issue: 1, Start page: e000998
Swansea University Authors:
Katherine Cullen , Mari Jones , Rhys Pockett , Deborah Fitzsimmons
-
PDF | Version of Record
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Download (427.11KB)
DOI (Published version): 10.1136/bmjgast-2022-000998
Abstract
AbstractObjective Hepatocellular carcinoma (HCC) incidence in the UK trebled between 1997 and 2017. With increasing numbers requiring treatment, understanding the likely impact on healthcare budgets can inform service planning and commissioning. The aim of this analysis was to use existing registry...
| Published in: | BMJ Open Gastroenterology |
|---|---|
| ISSN: | 2054-4774 |
| Published: |
BMJ
2023
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa63143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
AbstractObjective Hepatocellular carcinoma (HCC) incidence in the UK trebled between 1997 and 2017. With increasing numbers requiring treatment, understanding the likely impact on healthcare budgets can inform service planning and commissioning. The aim of this analysis was to use existing registry data to describe the direct healthcare costs of current treatments for HCC and estimate the impact on National Health Service (NHS) budgets.Design A retrospective data analysis based on the National Cancer Registration and Analysis Service cancer registry informed a decision-analytic model for England comparing patients by cirrhosis compensation status and those on palliative or curative treatment pathways. Potential cost drivers were investigated by undertaking a series of one-way sensitivity analyses.Results Between 1 January 2010 and 31 December 2016, 15 684 patients were diagnosed with HCC. The median cost per patient over 2 years was £9065 (IQR: £1965 to £20 491), 66% did not receive active therapy. The cost of HCC treatment for England over 5 years was estimated to be £245 million.Conclusion The National Cancer Registration Dataset and linked data sets have enabled a comprehensive analysis of the resource use and costs of secondary and tertiary healthcare for HCC, providing an overview of the economic impact to the NHS England of treating HCC. |
|---|---|
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
The programme of research was supported by the British Association for the Study of the Liver who received an unrestricted and unconditional award from BTG International Ltd. BTG did not have any input into the design, analysis, or interpretation of the data, writing of the manuscript, review of the manuscript, the decision to submit the manuscript or the writing of this statement. |
| Issue: |
1 |
| Start Page: |
e000998 |